- Get in Touch with Us
Last Updated: Apr 26, 2025 | Study Period: 2024-2030
Beggin is one of about three dozen individuals who have undergone brain implants for a device known as a "Utah array" for scientific study. The human brain is only two millimetres into the apparatus, which also has a tiny grid of electrodes.
Two patients were able to operate a computer by using only their thoughts thanks to the technology. In the long run, it could be used to identify and cure a variety of brain pathologies, including Parkinson's disease and epilepsy.
The Global smart brain implants market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Brain implant technology is launched by dAxoft to treat chronic neurological disorders, and it is given FDA breakthrough device designation.
They created novel implants that don't acquire gliosis. To put it another way, the implants can stay in the central nervous system for an extended period of time without causing damage.
Additionally, Axoft's implants have electrical stability to monitor brain signals over an extended period of time and deliver an incredibly high sensor density to maximise the amount of data that can be transmitted between the brain and electronics.
Technological advances in the semiconductor sector, the creation of new sophisticated materials, advancements in chip design, and developments in minimally invasive surgical techniques have made it possible to use neurotechnology in the clinic and actually benefit patients.
The desire for a higher quality of life is fueling the demand for less invasive, more potent neurological tools, which is being exacerbated by the rising cost of neurological diseases caused by an ageing population.
Ultra-high bandwidth and steady single-neuron measurements are made possible by Axoft's minimally invasive implants because they seamlessly interact with the nervous system.
Axoft's implant material enables it to remain functional as the brain shifts or grows, minimising the need for replacement and offering a long-term BMI to seamlessly connect the brain to electronics.
Whereas current implants have limited longevity and ability to track the same neurons in the brain over time, this technology can track the same neurons in the brain over time.
A crucial step for the brain implant startup Neuralink as it deals with American inquiries into its conduct of animal tests, the U.S. Food and Drug Administration (FDA) has approved Neuralink's first-in-human clinical trial.
A brain implant dubbed the Link is being developed by Neuralink with the goal of enabling patients with severe paralysis to operate external technology only using neural inputs. As a result, people who suffer from severe degenerative diseases like ALS may someday be able to type and move the cursor on a computer keyboard to connect with family and friends.
The Neuralink team worked incredibly hard on this in close cooperation with the FDA, and it is the product of their amazing efforts. This is a significant first step that will eventually enable their technology to assist a large number of people.
Neuralink is a part of the developing brain-computer interface (BCI) sector of the economy. A brain-computer interface (BCI) is a device that decodes brain impulses and converts them into instructions for external technology.
BCI technology has been the subject of years of scientific investigation, and a number of businesses have created promising products that they want to market. Receiving FDA approval for a commercial medical device, however, is no easy feat; it necessitates businesses to successfully complete numerous extraordinarily meticulous rounds of testing and data collection.
Patients who use Neuralink's BCI will need to have risky brain surgery. The Link, a tiny circular implant that interprets and analyses cerebral signals, serves as the hub of its system. A number of tiny, flexible threads that are put right into the brain tissue to sense neurological signals are connected to The Link.
Patients who have Neuralink devices will be taught how to operate them via the Neuralink app. According to the company's website, patients would then be able to use external mice and keyboards via a Bluetooth connection.Neuralink has recently faced a number of challenges, so the FDA's permission for an in-human trial is a huge victory for the firm.
In response to allegations that Neuralink packaged and shipped tainted technology in an unsafe manner, the U.S. Department of Transportation confirmed to CNBC that it has launched an inquiry into the company.
Activist groups have also criticised Neuralink for what they claim to be its abuse of animals. The Physicians Committee for Responsible Medicine, an organisation that opposes animal research, has repeatedly urged Musk to divulge information concerning monkey trials that led to internal bleeding, paralysis, persistent infections, seizures, worsening psychological health, and death.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2026 Mobility Foresights Pvt Ltd. All rights reserved.
Developed with by ClousTech